Experts discuss why anti-CCR8 antibody denikitug is being tested in phase 1 solid tumor trials
Dr Bruno B. Bockorny, a gastrointestinal oncologist at Beth Israel Deaconess Medical Center and assistant professor at Harvard Medical School, explained the scientific basis for testing the anti‑CCR8 antibody denikitug (GS‑1811) in a phase‑1 trial involving solid tumors.
He noted that regulatory T cells (Tregs) within tumors suppress immune responses and are associated with poorer patient outcomes, making them a key obstacle in modern oncology.
CCR8 has emerged as a highly specific marker that distinguishes intratumoral Tregs from those circulating in the peripheral blood, offering a way to selectively target the immunosuppressive cells inside the tumor microenvironment.
The trial aims to determine whether denikitug can safely reduce intratumoral Tregs and potentially improve the efficacy of existing cancer therapies, although clinical results have not yet been reported.
This writeup was produced by pharmadog from original reporting by onclive.
Original headline: “Dr Bockorny on the Rationale for Targeting CCR8 in Solid Tumors”
read at onclive ↗
comments(0)
5-min edit window · permanent after that